Mitochondrial modulation with leriglitazone as a potential treatment for Rett syndrome

Abstract excerpt

BACKGROUND: Rett syndrome is a neuropediatric disease occurring due to mutations in MECP2 and characterized by a regression in the neuronal development following a normal postnatal growth, which results in the loss of acquired capabilities such as speech or purposeful usage of hands. While altered neurotransmission and brain development are the center of its pathophysiology, alterations in mitochondrial...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Genetics and Neurodevelopmental Disorders
• Share to Neurogenetic and Muscular Disorders Research
• Share to Ubiquitin and proteasome pathways